ClinicalTrials.gg
CompletedNCT01674712Updated Dec 11, 2014Results posted

A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

A Phase 3 interventional study of Fixed Combination of Fenofibrate/simvastatin 145/20 mg and Simvastatin 20 mg in Dyslipidemia, sponsored by Abbott. Completed at 69 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-11.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
575
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing simvastatin in Dyslipidemias — none open to participants now, none under way, none of them phase 3. Simvastatin · Dyslipidemias.

Enrollment
7th of 20
575 · median 155
Started
2012
the only one that year
Phase 3
9 of 21
none open now
Registered
16th of 21
by date
Lead sponsor
1 of 21
Abbott

Among the 21 studies testing simvastatin in Dyslipidemias, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2012, is one of 9 in phase 3, and was the 16th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 21 studies testing simvastatin in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About simvastatin

Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing simvastatin in Dyslipidemias as a file.
02

Study summary

This is a double-blind, randomized study designed to compare the efficacy and safety of two fixed combinations of fenofibrate / simvastatin 145/20 mg and fenofibrate / simvastatin 145/40 mg tablets vs. matching monotherapies in subjects with abnormal fat (lipids) in the blood and at high risk of cardiovascular disease. Fenofibrate is a treatment that lowers fat in blood. It is prescribed in patients with high levels of triglycerides (TG). The drug has been marketed in more than 80 countries since 1975. Simvastatin is also used for the treatment of patients with a high level of cholesterol. These have also been marketed worldwide for more than 20 years. It is important to treat high levels of fats in the blood because it has been shown that even mildly elevated level of lipids in the blood can lead to diseases of the blood vessels. It has been shown in several studies and in clinical practice that the combination of fenofibrate plus simvastatin can lead to improved effects on blood fats, compared to treatment with simvastatin or fenofibrate alone. The main objective of the study is to compare the efficacy of the two fixed-combinations (FC) -fenofibrate/simvastatin 145/20 mg tablet and fenofibrate/simvastatin 145/40 mg tablet in reducing TG and increasing high density lipoprotein cholesterol (HDL-C) versus simvastatin 20 mg or 40 mg, and in reducing low density lipoprotein cholesterol (LDL-C) versus fenofibrate 145 mg.

03

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • Fibrates
  • Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Either gender (tentatively 50 percent females to be included and if of she must agree to use medically acceptable methods of from the time of signing the until 7 days following administration of the last treatment or dose of study medication). Accepted contraceptive methods are implants, injectables, combined oral contraceptives, intra-uterine device or sexual abstinence.
  2. between 18 (inclusive) and 80 years
  3. With mixed dyslipidemia with fasting lipid results of a blood sample taken at inclusion and after at least 3 months of any statin monotherapy (excluding simvastatin 80 mg, atorvastatin 40 mg and 80 mg, rosuvastatin 20 mg and 40 mg):

    • TG higher than/equal to 1.71 mmol/L (higher than/equal to 150 mg/dL) and
    • LDL-C higher or equal to 1.81 mmol/L (higher or equal 70 mg/dL) but smaller than/equal to 3.36 mmol/L (smaller than/equal to 130 mg/dL)
  4. High risk or very high risk based on known CardioVascular Disease (CVD) or type 2 diabetes or type 1 diabetes with microalbuminuria or a Systematic Coronary Risk Estimation (SCORE) chart risk ≥ 5percent
  5. and/or alanine aminotransferase smaller than/equal to 2 times the Upper Normal of Limit (UNL)

Exclusion criteria

Exclusion Criteria:

  1. Known to fibrates or simvastatin or known photoallergic or phototoxic reactions under treatment with fibrates or ketoprofen or known allergic reactions caused by peanuts, peanuts or arachis oil or soy lecithin, or related products,
  2. Pregnant or lactating women,
  3. Unable or unwilling to comply with the protocol and the recommended diet,
  4. Likely to withdraw from the study before its completion,
  5. Having received an drug or vaccine in the last 30 days before date of inclusion, or still participating in such a trial at Visit 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
575 participants (actual)

Study arms

  • Experimental
    Fenofibrate/simvastatin 145/20 mg

    Drug: Fixed Combination of Fenofibrate/simvastatin 145/20 mg

  • Active comparator
    Simvastatin 20 mg

    Drug: Simvastatin 20 mg

  • Active comparator
    Fenofibrate 145 mg

    Drug: Fenofibrate 145 mg

  • Experimental
    Fenofibrate/simvastatin 145/40 mg

    Drug: Fixed Combination of Fenofibrate/simvastatin 145/40 mg

  • Active comparator
    Simvastatin 40 mg

    Drug: Simvastatin 40 mg

Interventions

  • DrugFixed Combination of Fenofibrate/simvastatin 145/20 mg

    Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks

  • Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks

  • Fenofibrate, tablet, 145 mg, once daily, 12 weeks

  • DrugFixed Combination of Fenofibrate/simvastatin 145/40 mg

    Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks

  • simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Change of TG (Triglyceride)

    Collection and measurement of blood samples.

    Time frame: from baseline to 12 weeks of treatment

  2. Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)

    Collection and measurement of blood samples.

    Time frame: from baseline to 12 weeks of treatment

  3. Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)

    Collection and measurement of blood samples.

    Time frame: from baseline to 12 weeks of treatment

Secondary outcomes

  1. Percentage of Non-HDL (High Density Lipoprotein)-C From Baseline

    Collection and measurement of blood samples

    Time frame: 12 weeks

  2. Percentage of TC (Triglyceride) From Baseline

    Collection and measurement of blood samples

    Time frame: 12 weeks

  3. Percentage of Apolipoprotein AI From Baseline

    Collection and measurement of blood samples

    Time frame: 12 weeks

  4. Percentage of Apolipoprotein B From Baseline

    Collection and measurement of blood samples

    Time frame: 12 weeks

  5. Percentage of High-sensitivity C-reactive Protein (hsCRP) From Baseline

    Collection and measurement of blood samples

    Time frame: 12 weeks

  6. Percentage of Subjects Meeting Target Levels of Lipids (According to Very High or High Risk)

    Collection and measurement of blood samples

    Time frame: 12 weeks

  7. Adverse Events

    Collection and measurement of blood samples

    Time frame: 12 weeks

  8. Creatine Kinase (CK)

    Collection and measurement of blood samples

    Time frame: 12 weeks

  9. Alanine Aminotransferase (ALT)

    Collection and measurement of blood samples

    Time frame: 12 weeks

  10. Plasma Creatinine

    Collection and measurement of blood samples

    Time frame: 12 weeks

  11. Total Bilirubin

    Collection and measurement of blood samples

    Time frame: 12 weeks

  12. Cystatin C

    Collection and measurement of blood samples

    Time frame: 12 weeks

07

Results

Posted Oct 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneFenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mg
Started114117115116113
Full analysis subject sample109114110112111
Safety subject sample111117113115112
Completed104108106108102
Not completed1099811
Withdrew: Adverse event56346
Withdrew: Lost to follow-up10000
Withdrew: Protocol violation20000
Withdrew: Withdrawal by subject22543
Withdrew: Administrative01001
Withdrew: Lack of efficacy00101

Outcome measures

PrimaryPercentage of Change of TG (Triglyceride)

Collection and measurement of blood samples.

Time frame:
from baseline to 12 weeks of treatment
Reported as:
Mean · percentage of change
Percentage of Change of TG (Triglyceride)
percentage of changeFenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mg
Percentage of Change of TG (Triglyceride)-30.6 ± 25.810.7 ± 48.8-27.3 ± 35.9-2.9 ± 34.3-21.6 ± 34.2
PrimaryPercentage of Change of HDL-C (High Density Lipoprotein Cholesterol)

Collection and measurement of blood samples.

Time frame:
from baseline to 12 weeks of treatment
Reported as:
Mean · percentage of change
Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)
percentage of changeFenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mg
Percentage of Change of HDL-C (High Density Lipoprotein Cholesterol)9.0 ± 16.80.3 ± 12.18.8 ± 16.52.2 ± 12.57.6 ± 15.7
PrimaryPercentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)

Collection and measurement of blood samples.

Time frame:
from baseline to 12 weeks of treatment
Reported as:
Mean · percentage of change
Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)
percentage of changeFenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mg
Percentage of Change of LDL-C (Low Density Lipoprotein Cholesterol)1.9 ± 25.4-2.0 ± 24.8-6.1 ± 26.2-8.1 ± 25.830.3 ± 35.6
SecondaryPercentage of Non-HDL (High Density Lipoprotein)-C From Baseline

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryPercentage of TC (Triglyceride) From Baseline

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Apolipoprotein AI From Baseline

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Apolipoprotein B From Baseline

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryPercentage of High-sensitivity C-reactive Protein (hsCRP) From Baseline

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Subjects Meeting Target Levels of Lipids (According to Very High or High Risk)

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryAdverse Events

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryCreatine Kinase (CK)

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryAlanine Aminotransferase (ALT)

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryPlasma Creatinine

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryTotal Bilirubin

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

SecondaryCystatin C

Collection and measurement of blood samples

Time frame:
12 weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fenofibrate/Simvastatin 145/20 mg—3/111 (2.7%)8/111 (7.2%)
Simvastatin 20 mg—3/117 (2.6%)7/117 (6%)
Fenofibrate/Simvastatin 145/40 mg—3/113 (2.7%)4/113 (3.5%)
Simvastatin 40 mg—1/115 (0.9%)9/115 (7.8%)
Fenofibrate 145 mg—3/112 (2.7%)15/112 (13.4%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventFenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mg
ACUTE CORONARY SYNDROMECardiac disorders1/1110/1170/1130/1150/112
CEREBROVASCULAR ACCIDENTNervous system disorders1/1110/1170/1130/1150/112
HAEMATURIARenal and urinary disorders1/1110/1170/1130/1150/112
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/1110/1170/1130/1151/112
DIABETES MELLITUS INADEQUATE CONTROLMetabolism and nutrition disorders0/1110/1170/1130/1151/112
BURSITISMusculoskeletal and connective tissue disorders0/1110/1170/1130/1151/112
ANGINA PECTORISCardiac disorders0/1110/1171/1130/1150/112
VESTIBULAR DISORDEREar and labyrinth disorders0/1110/1171/1130/1150/112
INTESTINAL HAEMORRHAGEGastrointestinal disorders0/1110/1171/1130/1150/112
UMBILICAL HERNIA, OBSTRUCTIVEGastrointestinal disorders0/1110/1171/1130/1150/112
Most frequent other events
Most frequent other events
EventFenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mg
DIARRHOEAGastrointestinal disorders1/1112/1172/1130/1155/112
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations4/1110/1171/1131/1151/112
GASTROENTERITISInfections and infestations1/1112/1170/1130/1154/112
DYSPEPSIAGastrointestinal disorders1/1110/1170/1134/1151/112
NASOPHARYNGITISInfections and infestations1/1110/1171/1133/1153/112
COUGHRespiratory, thoracic and mediastinal disorders0/1113/1170/1131/1151/112

Baseline characteristics

Full analysis subject sample

Age, Continuous
Age, Continuous(years)Fenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mgTotal
Mean59.6 ± 1060.5 ± 9.360.4 ± 8.159.3 ± 9.160.4 ± 9.060.0 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Fenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mgTotal
Female3840433938198
Male7174677373358
Region of Enrollment
Region of Enrollment(participants)Fenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mgTotal
Czech Republic2222222321110
Mexico7987839
Argentina1922192021101
Poland79810741
Romania6665427
Russian Federation181716161784
Germany3029313133154
Triglycerides (mmol/L)
Triglycerides (mmol/L)(mmol/L)Fenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mgTotal
Mean2.8 ± 1.12.5 ± 1.02.7 ± 1.42.7 ± 1.02.9 ± 1.32.7 ± 1.1
LDL Cholesterol (mmol/L)
LDL Cholesterol (mmol/L)(mmol/L)Fenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mgTotal
Mean2.6 ± 0.52.6 ± 0.42.6 ± 0.42.7 ± 0.42.7 ± 0.52.7 ± 0.5
HDL Cholesterol (mmol/L)
HDL Cholesterol (mmol/L)(mmol/L)Fenofibrate/Simvastatin 145/20 mgSimvastatin 20 mgFenofibrate/Simvastatin 145/40 mgSimvastatin 40 mgFenofibrate 145 mgTotal
Mean1.1 ± 0.31.2 ± 0.31.2 ± 0.31.2 ± 0.31.2 ± 0.31.2 ± 0.3
08

Study locations

69 sites
  • Site Reference ID/Investigator# 77961
    Buenos Aires, 7600, Argentina
  • Site Reference ID/Investigator# 77957
    Buenos Aires, B1605DSX, Argentina
  • Site Reference ID/Investigator# 77958
    Buenos Aires, B1657BHD, Argentina
  • Site Reference ID/Investigator# 77960
    Buenos Aires, B1722COV, Argentina
  • Site Reference ID/Investigator# 77959
    Buenos Aires, B1878GEG, Argentina
  • Site Reference ID/Investigator# 77969
    Buenos Aires, B2800DGH, Argentina
  • Site Reference ID/Investigator# 77967
    Buenos Aires, C1179AAB, Argentina
  • Site Reference ID/Investigator# 77968
    Buenos Aires, C1181ACK, Argentina
  • Site Reference ID/Investigator# 77965
    Buenos Aires, C1405BCH, Argentina
  • Site Reference ID/Investigator# 77956
    Buenos Aires, Argentina
  • Site Reference ID/Investigator# 77966
    Cipolletti - Rio Negro, 8324, Argentina
  • Site Reference ID/Investigator# 77955
    Santa Fe, 3000, Argentina
  • Site Reference ID/Investigator# 77962
    Santa Fe, 3000, Argentina
  • Site Reference ID/Investigator# 77964
    Santa Fe, S2000DSV, Argentina
  • Site Reference ID/Investigator# 77963
    Tucuman, 4000JCU, Argentina
  • Site reference ID/Investigator # 99617
    Benatky nad Jizerou, 294 71, Czech Republic
  • Site Reference ID/Investigator# 80097
    Brno, 656 91, Czech Republic
  • Site reference ID/Investigator # 102335
    Brno, 65691, Czech Republic
  • Site Reference ID/Investigator# 80094
    Prague 10, 108 00, Czech Republic
  • Site Reference ID/Investigator# 80095
    Prague 4, 14059, Czech Republic
  • Site Reference ID/Investigator# 80093
    Praha 8, 18081, Czech Republic
  • Site Reference ID/Investigator# 80098
    Teplice, 415 01, Czech Republic
  • Site Reference ID/Investigator# 80096
    Usti nad Labem, 40113, Czech Republic
  • Site Reference ID/Investigator# 80099
    Znojmo, 669 02, Czech Republic
  • Site reference ID/Investigator # 97356
    Berlin, 10117, Germany
  • Site Reference ID/Investigator# 90673
    Berlin, 10249, Germany
  • Site Reference ID/Investigator# 80100
    Berlin, 12351, Germany
  • Site reference ID/Investigator # 97357
    Berlin, 13125, Germany
  • Site reference ID/Investigator # 102017
    Dortmund, 44137, Germany
  • Site reference ID/Investigator # 99876
    Dresden, 01069, Germany
  • Site Reference ID/Investigator# 80102
    Dusseldorf, 40597, Germany
  • Site Reference ID/Investigator# 80104
    Essen, 45355, Germany
  • Site Reference ID/Investigator# 80103
    Essen, 45359, Germany
  • Site Reference ID/Investigator# 80105
    Frankfurt, 60594, Germany
  • Site Reference ID/Investigator# 80101
    Goch, 47574, Germany
  • Site reference ID/Investigator # 99902
    Hamburg, 20253, Germany
  • Site reference ID/Investigator # 102015
    Karlsruhe, 76199, Germany
  • Site reference ID/Investigator # 102016
    Koeln, 51069, Germany
  • Site Reference ID/Investigator# 77970
    Guadalajara, Jal., C.P. 44130, Mexico
  • Site Reference ID/Investigator# 77973
    Mexico D.F., C.P. 06600, Mexico
  • Site Reference ID/Investigator# 77972
    Mexico D.F., C.P. 11850, Mexico
  • Site Reference ID/Investigator# 77974
    Zapopan, 45200, Mexico
  • Site Reference ID/Investigator# 80111
    Gdansk, 80-952, Poland
  • Site Reference ID/Investigator# 80112
    Gdansk, 80-952, Poland
  • Site Reference ID/Investigator# 80110
    Gdynia, 81-423, Poland
  • Site Reference ID/Investigator# 80106
    Katowice, 40-954, Poland
  • Site Reference ID/Investigator# 80109
    Plock, 09-400, Poland
  • Site Reference ID/Investigator# 80108
    Skierniewice, 96-100, Poland
  • Site Reference ID/Investigator# 80107
    Warsaw, 01-868, Poland
  • Site reference ID/Investigator # 80115
    Bucharest, 10242, Romania
  • Site Reference ID/Investigator# 80114
    Bucharest, 11172, Romania
  • Site Reference ID/Investigator# 80117
    Bucharest, 11794, Romania
  • Site Reference ID/Investigator# 80116
    Bucharest, 20054, Romania
  • Site Reference ID/Investigator# 80119
    Bucharest, 22328, Romania
  • Site Reference ID/Investigator# 80113
    Bucharest, 42122, Romania
  • Site Reference ID/Investigator# 80118
    Iasi, 700547, Romania
  • Site Reference ID/Investigator# 80120
    Kemerovo, 650002, Russian Federation
  • Site Reference ID/Investigator# 80135
    Moscow, 119435, Russian Federation
  • Site Reference ID/Investigator# 80137
    Moscow, 119620, Russian Federation
  • Site Reference ID/Investigator# 80124
    Moscow, 119991, Russian Federation
  • Site Reference ID/Investigator# 80127
    Moscow, 125284, Russian Federation
  • Site Reference ID/Investigator# 80122
    Novosibirsk, 630008, Russian Federation
  • Site Reference ID/Investigator# 80121
    Novosibirsk, 630047, Russian Federation
  • Site Reference ID/Investigator# 80133
    Novosibirsk, 630068, Russian Federation
  • Site reference ID/Investigator # 80134
    St. Petersburg, 194156, Russian Federation
  • Site reference ID/Investigator # 80126
    St. Petersburg, 197022, Russian Federation
  • Site reference ID/Investigator # 80128
    St. Petersburg, 197022, Russian Federation
  • Site Reference ID/Investigator# 80136
    St. Petersburg, 199106, Russian Federation
  • Site Reference ID/Investigator# 80125
    Yaroslavl, 150010, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2012
First posted
Aug 29, 2012
Start
Jun 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 30, 2014
Last update
Dec 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01674712
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
Aug 29, 2012
Start date
Jun 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 30, 2014
Last update
Dec 11, 2014

Study contacts

Jean-Claude Ansquer, MD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simvastatin

Start the discussion